In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

Most of us know someone that has been affected by diabetes. It can lead to severe health problems, such as eye problems, ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 programPivotal Phase 3 trials designed to leverage the ...

For Sprackling, the key to consumers benefiting from GLP-1 medications is responsible use rather than viewing them as a quick ...

Only 13 states currently offer Medicaid coverage for GLP-1 drugs, but the number of prescriptions and overall spending has ...

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive ...